# Drosophila-generated CTL

> **NCT01271907** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 3 (actual)

## Conditions studied

- Metastatic Cutaneous Melanoma

## Interventions

- **DRUG:** fludarabine
- **DRUG:** cyclophosphamide
- **DRUG:** Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ PBL
- **DRUG:** Aldesleukin

## Key facts

- **NCT ID:** NCT01271907
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-04-15
- **Primary completion:** 2011-12-08
- **Final completion:** 2011-12-08
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Study was terminated due to withdrawal of CRADA partner.
- **Last updated:** 2017-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01271907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01271907, "Drosophila-generated CTL". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01271907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*